During the past decade, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences conducted 136 clinical trials. In the 10-year time frame, 136 clinical trials started and 16 clinical trials were completed, i.e. on average, 11.8% percent of trials that started reached the finish line to date. In the past 5 years, 97 clinical trials started and 11 clinical trials were completed. i.e. 11.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences" #1 sponsor was "Institute of Hematology & Blood Diseases Hospital" with 20 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 11 trials sponsored, "BeiGene" with 8 trials sponsored, "Ascentage Pharma Group Inc." with 7 trials sponsored and "Hoffmann-La Roche" with 7 trials sponsored. Other sponsors include 88 different institutions and companies that sponsored additional 58 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences" #1 collaborator was "Tianjin Medical University Cancer Institute and Hospital" with 5 trials as a collaborator, "Henan Cancer Hospital" with 4 trials as a collaborator, "The Second Affiliated Hospital of Kunming Medical University" with 4 trials as a collaborator, "Tianjin Medical University Second Hospital" with 4 trials as a collaborator and "Qilu Hospital of Shandong University" with 3 trials as a collaborator. Other collaborators include 61 different institutions and companies that were collaborators in the rest 57 trials.

According to Clinical.Site data, the most researched conditions in "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences" are "Hemophilia A" (15 trials), "Multiple Myeloma" (9 trials), "Chronic Lymphocytic Leukemia" (7 trials), "Small Lymphocytic Lymphoma" (5 trials) and "Acute Myeloid Leukemia" (4 trials). Many other conditions were trialed in "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences" in a lesser frequency.

Most popular intervention types in "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences" are "Drug" (130 trials), "Biological" (11 trials), "Other" (4 trials), "Procedure" (4 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "Zanubrutinib" (9 trials), "Placebo" (8 trials), "Rituximab" (8 trials), "Dexamethasone" (7 trials) and "Azacitidine" (6 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences" are 129 trials for "All" genders and 17 trials for "Male" genders.

Currently, there are 86 active trials in "Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences". 1 are not yet recruiting, 63 are recruiting, 21 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 26 completed trials in Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, 43 "Phase 1" clinical trials were conducted, 46 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 11 trials that are defined as “Not Applicable".